Which was the first vaccine prepared by India for COVID-19?

NORCET 2 - 2021 (shift-1)

Applied Microbiology & Infection control

Easy

Appeared in: NORCET 2 - 2021 (shift-1)

Explanation

Covaxin was India's first indigenously developed COVID-19 vaccine, created by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
It is a whole-virion inactivated virus vaccine, a traditional and well-established platform for vaccine development.
The key differentiator is 'prepared by India', which implies indigenous development, distinguishing it from Covishield, which was manufactured in India but developed in the UK.

Option A: Moderna is an mRNA vaccine developed and manufactured in the United States. It was not prepared by India.
Option B: Although manufactured on a large scale by the Serum Institute of India, Covishield was developed by Oxford University and AstraZeneca in the UK. It was not the first vaccine 'prepared' or 'developed' by India.
Option C: Sputnik V is a viral vector vaccine developed by the Gamaleya Research Institute in Russia. It was imported and later approved for manufacturing in India, but not developed there.

Visual 1: Infographic: A timeline showing the development and approval dates of Covaxin and Covishield in India.
Visual 2: Chart: A comparative chart of different COVID-19 vaccine platforms (Inactivated, Viral Vector, mRNA) with examples.
Visual 3: Image: A picture of a Covaxin vial and a Covishield vial side-by-side to help with visual recognition.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Knowledge of COVID-19 vaccines available in India and their origins as background academic context rather than a clinical decision trigger.
Nurses play a vital role in vaccine administration, which includes verifying the correct vaccine, dose, and storage conditions. Knowing the difference between vaccines like Covaxin and Covishield is essential for patient safety and accurate record-keeping.
Maintaining the cold chain (2-8°C for most vaccines in India) is a critical nursing responsibility. A break in the cold chain can render the vaccine ineffective.
Patient education is key. Nurses must be prepared to answer patient questions about different vaccines, their origins, and potential side effects to address vaccine hesitancy.

How to Approach the Question

First, identify the key phrases in the question: 'first vaccine' and 'prepared by India'.
Understand that 'prepared by India' implies indigenous development, not just manufacturing.
Recall or look for information about the origins of the four vaccines listed in the options.
Evaluate each option: Moderna (USA), Covishield (UK development, Indian manufacturing), Sputnik (Russia), and Covaxin (Indian development).
Based on the 'indigenous development' criterion, identify Covaxin as the correct answer.
Differentiate Covaxin from Covishield, which is a common point of confusion, by remembering that Covishield was developed abroad.

Concept Tested & Keywords

Concept Tested: Knowledge of COVID-19 vaccines available in India and their origins.
Stem keywords: first vaccine, prepared by India, COVID-19
Lead-in keywords: Which
Negative lead-in flag: false

QeGCQvPvCSaAQxONTDIP_3